Condition
Lymphoproliferative Disorder clinical trials and research
As of November 12, 2026, Find a Trial lists 6 Lymphoproliferative Disorder clinical trials that are recruiting, at sites in 6 countries (most in United States (6), Australia (1), Canada (1)). By phase: Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 6Countries
Newest Lymphoproliferative Disorder clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Understanding blood cell issues after CAR-T therapy for multiple myeloma or lymphoproliferative disorders | — | Scottsdale, Arizona and 6 other locations | Recruiting | Oct 8, 2024 |
| Combining acalabrutinib and obinutuzumab to treat untreated follicular lymphoma and indolent non-Hodgkin lymphomas | Phase 2 | Atlanta, Georgia | Recruiting | May 12, 2021 |
| Using Nivolumab to treat EBV-positive lymphoproliferative disorders and non-Hodgkin lymphomas | Phase 2 | Bethesda, Maryland | Recruiting | Aug 23, 2017 |
| Gathering health information for younger cancer patients | — | Birmingham, Alabama and 278 other locations | Recruiting | Mar 30, 2015 |
| Registry of older patients with cancer | — | Boone, North Carolina and 6 other locations | Recruiting | Jun 4, 2010 |
| Collection of tissue, blood, and body fluid samples from patients with hematologic cancer | — | Chapel Hill, North Carolina | Recruiting | Jun 4, 2010 |
All recruiting trials (6)
-
Understanding blood cell issues after CAR-T therapy for multiple myeloma or lymphoproliferative disorders
This study is testing how certain genetic differences in people with multiple myeloma or lymphoproliferative disorders affect their chances of developing low blood cell counts after CAR-T therapy.
-
Combining acalabrutinib and obinutuzumab to treat untreated follicular lymphoma and indolent non-Hodgkin lymphomas
This study is testing if combining two treatments, acalabrutinib and obinutuzumab, can help people with untreated follicular lymphoma and other slow-growing non-Hodgkin lymphomas feel better and improve their quality of life.
-
Using Nivolumab to treat EBV-positive lymphoproliferative disorders and non-Hodgkin lymphomas
This study is testing if a new drug called Nivolumab can help people aged 12 and older with certain types of lymphomas that are linked to the Epstein-Barr Virus and haven't improved with other treatments.
-
Gathering health information for younger cancer patients
This study is gathering health information from younger cancer patients to help improve treatments and support future research.
-
Registry of older patients with cancer
This study collects health information from older cancer patients to create a registry that helps improve care and research for seniors with cancer.
-
Collection of tissue, blood, and body fluid samples from patients with hematologic cancer
This study is collecting tissue, blood, and body fluid samples from patients with blood cancers to help improve cancer research and patient care.
Related topics
Quick answers
How many Lymphoproliferative Disorder clinical trials are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 6 countries. The most sites are in United States (6 trials), Australia (1 trial), Canada (1 trial), New Zealand (1 trial), Puerto Rico (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.